Howe Named Chief Financial Officer at DTx Pharma
8 June 2021 - - US-based biotechnology company DTx Pharma, Inc has appointed Jill Howe as chief financial officer, the company said.

Howe brings proven capabilities in private and public financial management, and will oversee all aspects of DTx's finances.

Howe brings to the role more than 20 years of finance experience in the biotechnology sector, including a track record of success in operational and financial strategy, as well as treasury, global infrastructure, and compliance management.

Prior to joining DTx, Howe served as treasurer and vice president of Finance for Gossamer Bio, a clinical-stage biopharmaceutical company, where she was the internal project lead for the company's initial public offering, follow-on, and debt offerings.

In addition to building a successful finance team at Gossamer Bio, she oversaw finance for 18 subsidiaries across the US and Ireland. Previously, Howe held controller and director of finance roles at Amplyx Pharmaceuticals, Receptos, and Somaxon Pharmaceuticals.

DTx Pharma, Inc. is a privately-held biotechnology company based in San Diego, CA creating novel RNA-based therapeutics to treat the genetic drivers of disease.